The evaluation presented at SABCS last week highlighted the importance of considering node-positive and -negative patients, and incorporating clinical information with molecular tests.
The agreement lets Biotheranostics offer its CancerType ID and Breast Cancer Index genomic tests to customers through Syapse's software.
The diagnostics company reported organic sales increased 4 percent in Q4 and 7 percent in 2015, and set a growth target of 6 percent to 8 percent for 2016.
The molecular diagnostics developer will use the money to continue expanding its commercial presence in the cancer diagnostics market.
The companies will investigate the feasibility of using BioTheranostics’ proprietary biomarkers and DeNovos CTC platform for blood-based diagnostics.
NEW YORK (GenomeWeb) – BioTheranostics today said that it has received a positive coverage and reimbursement evaluation from a Medicare contractor for its Breast Cancer Index test.
BioTheranostics Nicolas Barthelemy its new president and CEO. He succeeds Richard Ding, who will remain chairman of the board of bioTheranostics in addition to heading the Asia Pacific operations for parent company bioMérieux.
Originally published Sept. 22.
NEW YORK (GenomeWeb) – The New York State Department of Health has approved BioTheranostics to offer its Breast Cancer Index to residents in the state, the company said today.
This story has been updated to clarify the current state of the Tissue of Origin test formerly of Pathwork Diagnostics, now owned and marketed by Response Genetics.
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.